Maré et al. [33] studied serum SOST levels in patients with end-stage renal disease (ESRD) and found that a serum SOST level assay can be used as a biomarker for bone metabolism disorders in patients with ESRD. Here, SOST is linked to stage 5 chronic kidney disease.